<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03047330</url>
  </required_header>
  <id_info>
    <org_study_id>2016P002821</org_study_id>
    <nct_id>NCT03047330</nct_id>
  </id_info>
  <brief_title>Menopausal Sleep Fragmentation and Body Fat Gain</brief_title>
  <official_title>Menopausal Sleep Fragmentation: Impact on Body Fat Gain Biomarkers in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the impact of menopause-related sleep fragmentation on
      metabolic biomarkers of body fat gain. The investigators hypothesize that experimental sleep
      fragmentation will result in an adverse leptin response as a metabolic biomarker for body fat
      gain.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2017</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in leptin level</measure>
    <time_frame>3 days</time_frame>
    <description>Within-person comparison of change in leptin level after fragmented sleep compared with change in leptin level after unfragmented sleep.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>Unfragmented sleep</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive one dose of Leuprolide Acetate and will have some unfragmented sleep periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fragmented sleep</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive one dose of Leuprolide Acetate and will have some fragmented sleep periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide Acetate</intervention_name>
    <description>one injection of open-label intramuscular dose of leuprolide (3.75-mg depot), a gonadotropin-releasing hormone agonist that rapidly suppresses estradiol and temporarily achieves ovarian suppression.</description>
    <arm_group_label>Unfragmented sleep</arm_group_label>
    <arm_group_label>Fragmented sleep</arm_group_label>
    <other_name>Lupron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fragmented sleep</intervention_name>
    <description>Fragmented sleep will be experimentally induced.</description>
    <arm_group_label>Fragmented sleep</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy premenopausal women 21-45 years old

          -  Regular sleep schedule

          -  Limited alcohol and caffeine intake

          -  Regular monthly menstrual cycles

          -  No lifetime history of hot flashes

          -  Willingness to use approved methods of contraception during study

          -  Not obese

          -  Good general health

        Exclusion Criteria:

          -  Contraindication, hypersensitivity or previous adverse reaction to gonadotropin
             releasing hormone agonists

          -  Pregnancy

          -  Breastfeeding

          -  Tobacco use

          -  Contraindicated systemic hormone medications or centrally active medications

          -  Shift workers or recent/expected time zone travel

          -  Obstructive sleep apnea

          -  Insomnia symptoms

          -  Diagnosis of osteoporosis or osteopenia

          -  Hypothalamic-pituitary-adrenal axis disorders

          -  Diabetes

          -  Gastric bypass, metabolic disorders, or other related conditions

          -  Abnormalities on screening laboratory tests

          -  Substantial hearing impairment

          -  Cardiovascular illness

          -  Neurological illness

          -  Recent psychiatric illness or substance-use disorder
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aleta Wiley, MPH</last_name>
    <phone>6175259627</phone>
    <email>awiley1@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleta Wiley, MPH</last_name>
      <email>awiley1@bwh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2017</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Hadine Joffe, MD MSc</investigator_full_name>
    <investigator_title>Vice Chair for Psychiatry Research</investigator_title>
  </responsible_party>
  <keyword>menopause</keyword>
  <keyword>sleep fragmentation</keyword>
  <keyword>leuprolide</keyword>
  <keyword>adipokine</keyword>
  <keyword>weight gain</keyword>
  <keyword>leptin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Deprivation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

